|
Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer Clinical research trials and Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer. Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer clinical trial. Test subjects typically receive the most effective healthcare possible for their Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer  Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer
Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer
For Condition: Ovarian Neoplasms
Status: Recruiting
Sponsor(s): OSI Pharmaceuticals ,
Synopsis: The purpose of this study is to estimate the efficacy and safety of OSI-211 and topotecan in patients with relapsed epithelial ovarian cancer.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: Inclusion Criteria: - Confirmed relapsed ovarian cancer. - Measurable disease greater than or equal to 20 mm (or greater than or equal to 10 mm on spiral CT scan). - One or two prior regimens of chemotherapy. At least one regimen must have contained cisplatin or carboplatin. - At least three weeks since prior chemotherapy and recovery from any related toxicities. - At least four weeks since prior radiotherapy and recovery from any related toxicities.
Total Enrollment: 80
Location and Contact Information:
Royal Surrey County Hospital *Recruiting*
Guildford, Surrey, , GU2 7XX
United Kingdom
Recruiting OSIP Information (800) 572-1932
The Sarah Cannon Cancer Center, Centennial Medical Center *Recruiting*
Nashville, Tennessee, 37203
United States
Recruiting OSIP Information 800-572-1932
Beatson Oncology Centre *Recruiting*
Glasgow, , G11 6NT
United Kingdom
Recruiting OSIP Information (800) 572-1932
Northern Centre for Cancer Research, Newcastle General Hospital *Recruiting*
Newcastle upon Tyne, , NE4 6BE
United Kingdom
Recruiting OSIP Information (800) 572-1932
Royal Marsden NHS Trust *Recruiting*
London, , SW3 6JJ
United Kingdom
Recruiting OSIP Information (800) 572-1932
Taunton & Somerset Hospital *Recruiting*
Taunton, , TA1 5DA
United Kingdom
Recruiting OSIP Information (800) 572-1932
St Chad's Unit *Recruiting*
Birmingham, , B18 7QH
United Kingdom
Recruiting OSIP Information (800) 572-1932
NYU- Kaplan Comprehensive Cancer Center *Recruiting*
New York City, New York, 10016
United States
Recruiting OSIP Information 800-572-1932
Mount Vernon Hospital *Recruiting*
Northwood, Middlesex, , HA6 2RN
United Kingdom
Recruiting OSIP Information (800) 572-1932
CRC Department of Medical Oncology *Recruiting*
Sutton Surrey, , SM2 5PT
United Kingdom
Recruiting OSIP Information (800) 572-1932
Medical Oncology Unit, Torbay District General Hospital *Recruiting*
Torquay, , TQ2 7AA
United Kingdom
Recruiting OSIP Information (800) 572-1932
Additional Information:
Study ID Numbers: 110-20;
Study Start Date: September 2002
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00046800
Other Ovarian Neoplasms Studies:
1. Removal of the ovaries/fallopian tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
2. EPO906 Therapy in Patients with Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
3. A Safety and Effectiveness Study of Aroplatin in Patients with Advanced Solid Malignancies
4. Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined with Gemcitabine in Patients with Ovarian Cancer
5. Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer
Related Studies:
Other Ovarian Neoplasms Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer
|
|
|
|
|
|
|
|
